NasdaqCM - Delayed Quote USD

Organovo Holdings, Inc. (ONVO)

1.0000

-0.0300

(-2.91%)

At close: 4:00 PM EDT

Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo

SAN DIEGO, April 15, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration of clinical promise in three-dimensional (3D) human tissues, today released the complete details of its 16-week, randomized, placebo-controlled, multi-center Phase 2 study of the non-steroidal, non-bile acid FXR agonist FXR314 for the treatment of metabolic function-associated steatohepatitis (MASH). St

GlobeNewswire 8 days ago

ONVO
-2.91%
Top 15 3D Printing Companies in the US

In this article, we will take a look at the top 15 3D printing companies in the US. If you want to skip our detailed analysis, you can go directly to Top 5 3D Printing Companies in the US. Recent Trends in 3D Printing According to a report by Grand View Research, the global 3D […]

Insider Monkey 25 days ago

GE

HPQ

ONVO
-2.91%
Organovo Holdings Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Organovo Holdings ( NASDAQ:ONVO ) Third Quarter 2024 Results Key Financial Results Net loss: US$3.60m (loss widened by...

Simply Wall St. 2 months ago

ONVO
-2.91%
ONVO Continues Progress

By Brad Sorensen, CFA NASDAQ:ONVO READ THE FULL ONVO RESEARCH REPORT Organovo (NASDAQ:ONVO) reported its fiscal 3Q earnings and results were roughly inline with our expectations and illustrate to us that the company continues to progress toward bringing important products to market. Specifically, the company reported: • Earnings of -$0.40 per share, inline with estimates as expenses remained

Zacks Small Cap Research 2 months ago

ONVO
-2.91%
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress

SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis, based on demonstration of clinical promise in three-dimensional (3D) human tissues, today announced the presentation of preclinical data related to the company’s FXR314 development program in its proprietary 3D human tissue models of Crohn’s disease and ulcerative colitis at the

GlobeNewswire 2 months ago

ONVO
-2.91%
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress

SAN DIEGO, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as strong preclinical data, today announced that its data on the activity of FXR314 in its proprietary 3D human tissue models of Crohn’s disease and ulcerative colitis will be

GlobeNewswire 3 months ago

ONVO
-2.91%
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results

SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and inflammatory bowel disease (IBD), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as strong preclinical data, today announced that it will release final and complete data from a Phase 2a trial of FXR314 in non-alcoholic steatohepatitis (NASH) patients by April 2024. The

GlobeNewswire 4 months ago

ONVO
-2.91%
CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan

SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 8, 2023 by Organovo, Inc. (NASDAQ: ONVO), a link was incorrect. The corrected release follows: Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and inflammatory bowel disease (IBD), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as strong preclinical data, today ann

GlobeNewswire 5 months ago

ONVO
-2.91%
OVNO Continues Developing Breakthrough Treatments

By Brad Sorensen, CFA NASDAQ:ONVO READ THE FULL ONVO RESEARCH REPORT Organovo (NASDAQ:ONVO) reported its fiscal 2Q earnings and results were roughly inline with our expectations and illustrate to us that the company continues to progress toward bringing important products to market. Specifically, the company reported: • Earnings of -$0.46 per share, in line with estimates as expenses remained

Zacks Small Cap Research 5 months ago

ONVO
-2.91%
Organovo Holdings Second Quarter 2024 Earnings: US$0.46 loss per share (vs US$0.38 loss in 2Q 2023)

Organovo Holdings ( NASDAQ:ONVO ) Second Quarter 2024 Results Key Financial Results Net loss: US$3.99m (loss widened by...

Simply Wall St. 5 months ago

ONVO
-2.91%
Organovo Highlights FXR314 Combination Therapy Potential and Plan

SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and inflammatory bowel disease (IBD), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as strong preclinical data, today announced its intention to study combination therapy in inflammatory bowel disease and release data in calendar Q3 2024. The Company believes that the dat

GlobeNewswire 5 months ago

ONVO
-2.91%
ONVO: A Company With Great Technology to Impact Health Care

By Brad Sorensen, CFA NASDAQ:ONVO READ THE FULL ONVO RESEARCH REPORT Organovo Holdings (NASDAQ:ONVO) is a biotechnology company that is both a developer of 3D tissue technology that has the potential to change the way treatments are discovered and tested, as well as being a creator of new therapies using that technology, the focus of which is currently around the intestinal area and inflammatory

Zacks Small Cap Research 6 months ago

ONVO
-2.91%
Organovo to Participate in the H.C. Wainwright Global Investment Conference

SAN DIEGO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with high fidelity in three-dimensional (3D) human tissues that recapitulate key aspects of human disease, today announced that Keith Murphy, Founder and Executive Chairman, will present a corporate update and hold meetings with institutional investors during the H.C. Wainwright 25th Annual Global Investment Co

GlobeNewswire 7 months ago

ONVO
-2.91%
Is Organovo Holdings (ONVO) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap

Unpacking the Financial Health of Organovo Holdings Inc (ONVO) to Determine Its Investment Viability

GuruFocus.com 7 months ago

ONVO
-2.91%
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

SAN DIEGO, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with demonstrated function in high fidelity three-dimensional (3D) tissues that recapitulate key aspects of human disease, today announced more details about its clinical program for FXR314, an FXR agonist that has completed initial clinical trials. FXR314 is a drug with safety and tolerability after daily oral

GlobeNewswire 7 months ago

ONVO
-2.91%
Net Asset Value(s)

LONDON, July 12, 2023-- FundsDate

Business Wire 9 months ago

ONVO
-2.91%
Cathie Wood is Selling These 12 Stocks in 2023

In this article, we will take a look at Cathie Wood selling these 12 stocks in 2023. To see more such companies, go directly to Cathie Wood is Selling These 5 Stocks in 2023. After a bruising 2022, Cathie Wood’s funds slowly started to recover this year, thanks to the broader rally in the stock […]

Insider Monkey 10 months ago

CGEN
+4.76%
NIU

MGIC

Performance Overview

Return	ONVO	S&P 500
YTD	-9.91%	+6.30%
1-Year	-51.22%	+22.67%
3-Year	-89.07%	+22.63%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Organovo Holdings, Inc. (ONVO)

Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo

Top 15 3D Printing Companies in the US

Organovo Holdings Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

ONVO Continues Progress

Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress

Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress

Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results

CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan

OVNO Continues Developing Breakthrough Treatments

Organovo Holdings Second Quarter 2024 Earnings: US$0.46 loss per share (vs US$0.38 loss in 2Q 2023)

Organovo Highlights FXR314 Combination Therapy Potential and Plan

ONVO: A Company With Great Technology to Impact Health Care

Organovo to Participate in the H.C. Wainwright Global Investment Conference

Is Organovo Holdings (ONVO) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap

Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

Net Asset Value(s)

Cathie Wood is Selling These 12 Stocks in 2023

Performance Overview